dual gip glp 1 receptor agonists GIPR/GLP-1R agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications Polyagonists Enable Increasingly Effective Treatment
Description
Individual results may vary
Online Journal | Justin Plank | January 2025 Background Every year, the United States spends an estimated $173 billion treating obesity-related diseases like diabetes and heart disease, more than the annual budgets of 42 U.S
These efforts aim to establish novel roles for GLP-1RAs in cancer prevention
THURSDAY, Dec
A glucagon-like peptide-1 (GLP-1) drug appears to slow cognitive decline by protecting the brain, according to Phase 2b clinical trial results reported at AAIC.
Observational studies in autoimmune rheumatic diseases (ARDs) such as rheumatoid arthritis and systemic lupus erythematosus indicate
